The Medicines Manufacturing Industry Partnership (MMIP) represents the voice of medicines manufacturers in the UK. It was established jointly by Government and the biopharmaceutical industry in 2014 to ensure that the UK is recognised by the global medicines industry as a world-class, advanced centre for medicines manufacturing.
The UK's medicine industry is one of the country's leading manufacturing sectors, with exports worth over £20bn. The Partnership wants to ensure that the UK continues to be an attractive place for this high-value industry to secure exports, provide high skilled job opportunities and contribute to solving the country's productivity puzzle.
Click here to view the latest news and publications from the MMIP.
Working closely with key government organisations including the Medicines and Healthcare products Regulatory Authority (MHRA), UK Trade and Investment (UKTI), Innovate UK and the Office for Life Sciences (OLS), MMIP is examining the UK's position in medicines manufacturing and identifying opportunities for improvement.
The MMIP is divided into five workstreams. All of these workstreams are supported by overarching communications work and building the manufacturing community to ensure it speaks with one voice.
These workstreams are:
The MMIP also works to build the medicines manufacturing community.
MMIP is supported by the ABPI, the BioIndustry Association (BIA) and the Knowledge Transfer Network, and includes leadership from Allergan Biologics, AstraZeneca, Eisai, FUJIFILM Diosynth Biotechnologies, GlaxoSmithKline, Pfizer and ReNeuron. It has a senior project director, employed by the ABPI, and additional dedicated resources provided by partners.
For more information please contact the MMIP Operations Team:
You can keep up to date via our Twitter hashtag #MMIP, by following tweets from @ABPI_UK or @BIA_UK or by joining our LinkedIn group.